Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Hezbollah field commander killed in IDF strikes in Beirut - 2Watch Chinese astronauts enjoy '1st ever space BBQ' from Tiangong's brand-new oven (video)
- 3UN chief calls on Yemen's Houthi rebels to free all UN detainees
- 4Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- 5Poland open to German troops to help secure Ukraine ceasefire
- 10 High priority Contraptions for Tech Aficionados
- Germany sees third consecutive diesel price record after rule change
- Women take pride in Holy Week roles after a Spanish Catholic brotherhood's procession excluded them
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Culinary Joys: Investigating Connoisseur Cooking at Home
- Instructions to Back Your Sunlight powered chargers: Tracking down Possible Choices
- German unemployment rate falls to 6.4%, but 3 million still jobless
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
